Mesenchymal stem/stromal cells (MSC) are promising candidates for use in cell-based therapies. (typically 500-750 g 4), which can be harvested aseptically during cesarean section with no risk to the donor. MSC derived from placenta have long-term proliferation 5 and immunomodulatory capacity 6, superior to bone marrow-derived MSC. In a previous study, we demonstrated that a […]